Mumbai, March 30. Nazara Technologies Limited (BSE: 543280 | NSE: NAZARA), India’s leading diversified gaming and sports media company, today announced a preferential issue of warrants aggregating to INR 500 crores, subject to shareholder and regulatory approvals.

Each warrant is convertible into one equity share and is being issued at a price of INR 260 per share, representing a premium to the current market price, reflecting strong investor confidence in Nazara’s growth strategy.

The round includes participation from Riambel Capital PCC, a SEBI-registered Category I Foreign Portfolio Investor, S Gupta Family Investments, Plutus Investment and Holding Private Limited (Promoter Group), Classic Enterprises, and Founders Collective.

The participation from the Promoter Group at the issue price further reinforces alignment and long-term confidence in the Company’s growth strategy.

The proceeds from this fundraise will primarily be used to support strategic acquisitions, including the recently announced Bluetile and BestPlay transaction, and to accelerate growth across the existing business verticals of the Company.

Nitish Mittersain, Jt. MD & CEO, Nazara Technologies said,“This INR 500 crore fundraise comes at an important phase in Nazara’s journey as we execute on our most ambitious growth initiatives, including the Bluetile and BestPlay acquisition. This fresh capital, combined with our acquisition strategy, positions Nazara to build globally scalable, AI-enabled gaming businesses and further strengthen our leadership in the sector.” 

—

BioRestorative Therapies Reports Positive  Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease

MELVILLE, N.Y., March 30, 2026 — BioRestorative Therapies, Inc. (“BioRestorative,” “BRTX,” or the “Company”) (Nasdaq:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announced blinded data from its Phase 2 clinical trial evaluating hypoxic-cultured mesenchymal stem cells for the treatment of chronic lumbar disc disease, with 50% or more of treated patients reporting improvements >50% across key pain and functional outcome measures and no adverse events related to dose-limiting toxicities.  Importantly, the Phase 2 study efficacy endpoint is a greater than a 30% improvement in both the Visual Analog Scale (VAS) and Oswestry Disability Index (ODI) at 52 weeks, which is the minimum improvement needed to meet clinical efficacy success. Chronic lumbar disc disease is a leading cause of chronic lower back pain and disability, affecting millions of patients globally and representing a significant unmet need for non-surgical regenerative therapies.

These data were presented at the 2026 Orthopaedic Research Society Annual Meeting on March 28, 2026 at the Charlotte Convention Center in Charlotte, North Carolina. The Company delivered these data in a presentation titled, “Late-Stage Phase 2 Clinical Safety and Efficacy Data on Intradiscal Injections of Hypoxic Cultured Mesenchymal Stem Cells: Study Update.”

“These blinded data further support the therapeutic potential of our hypoxic-cultured mesenchymal stem cell technology, with  patients demonstrating meaningful improvements across key pain and functional outcome measures,” said Lance Alstodt, BioRestorative Therapies President, Chief Executive Officer, and Chairman.  “Even with blinded data, this signal provides us with confidence in the ultimate outcome of the study, and optimism moving forward with regard to the ultimate potential for meeting a medical need that has, to date, been inadequately addressed.

“Importantly, the results also continue to reinforce the favorable safety and tolerability profile observed to date. In addition, following our recent Type B meeting with the U.S. Food and Drug Administration, we achieved alignment on key elements of a potential Phase 3 clinical trial for BRTX-100, including primary endpoints, statistical powering assumptions, dosing strategy, and the overall development framework. The agency did not raise safety concerns and confirmed that our CMC framework is appropriate for late-stage development.

“Taken together, these developments position the Company to transition from clinical evaluation toward registrational planning. As we move toward the planned unblinding of the Phase 2 study, we have begun preparing for the next stage of clinical development, including protocol planning and other Phase 3 readiness activities, while continuing to generate additional clinical data that may support the advancement and potential commercialization of BRTX-100,” concluded Mr. Alstodt.

Clinically meaningful improvements in both pain and functional outcomes were observed across multiple validated pain and function measures, including the Visual Analog Scale (“VAS”), Oswestry Disability Index (“ODI”), Roland-Morris Disability Questionnaire (“RMDQ”), and Functional Rating Index (“FRI”), with responses sustained for up to two years in patients with longer-term follow-up.

On the VAS for pain, 53.57% of patients reported greater than 50% improvement at 26 weeks (n=28), with the percentage of patients that reported greater than 50% improvement increasing to 75% at 52 weeks (n=12) and remaining 75% at 104 weeks (n=4).

Similar improvements were observed on the ODI, a widely used measure of functional impairment associated with spinal disorders.  Blinded results from the abstract showed 53.57% of patients achieved greater than 50% improvement at 26 weeks (n=28), increasing to 74.63% of patients at 52 weeks (n=12), with 50% of patients maintaining that level of improvement at 104 weeks (n=4).

Improvements were also observed on the RMDQ, with 57.14% of patients experiencing greater than 50% improvement at 26 weeks (n=28), 50% of patients at 52 weeks (n=12), and 75% of patients at 104 weeks (n=4).

FRI demonstrated continued improvement over time, with 35.71% of patients achieving greater than 50% improvement at 26 weeks (n=28), increasing to 66.67% of patients at 52 weeks (n=12) and 50% of patients at 104 weeks (n=4).

Finally, at 26 weeks (n=28) 41% of patients reported a 50% improvement in both ODI and VAS, 55% of patients achieved a 50% improvement in both ODI and VAS at 52 weeks (n=12), and at 104 weeks (n=4) 57% of patients met a 50% improvement in both ODI and VAS.

London, UK—30th March, 2026— Metals.io, a new application for investing in and trading tokenized commodities, is live in the Tezos ecosystem. Developed by a team at Trilitech, a London-based Tezos R&D hub, the web app unlocks access to a selection of rare-earth metals, as well as base metals and minerals that are critical to the technology sector and the AI boom. Designed from the ground up as a single entry-point to a range of tokenized assets, metals.io launches with a dedicated and user-centric web app, which enables users to search for and add a range of tokenized commodities to their portfolios. Metals.io benefits from Tezos’ smart-rollup technology, which boasts sub-50ms latency, meaning that traders on the platform enjoy near-instant transaction confirmations, giving them the critical advantage they need in this dynamic market. 

Metals.io is launching at a pivotal moment, as demand for critical minerals and precious metals has intensified recently, driven on one hand by industrial applications and on the other by investors seeking portfolio diversification options in the face of economic uncertainty. The U.S. government’s establishment of a U.S. critical mineral reserve has led to further attention on these assets, which are essential to modern manufacturing and used in everything from smartphones to wind turbines and fighter jets. Metals.io launches with a number of these tokenized assets already live, with more to be added in the coming months. From today, visitors to the site can access xU3O8 tokenized uranium; VNX Gold (VNXAU), digital proof of ownership of allocated gold which is physically held in a high-security vault in Liechtenstein; and the RARE token from Noemon Tech, which provides transparent exposure to a diversified basket of five strategic metals selected for their critical industrial and technological value. 

“The current rapid pace of innovation in the AI sector and several other related fields is having a knock-on effect on demand for metals and materials that are critical to these endeavors. RARE enables users to gain digital ownership of a diversified basket of strategic metals – including elements such as hafnium, rhenium, indium, neodymium oxide, and praseodymium oxide – all of which are key to modern technologies and industrial applications. The team at Trilitech has developed an incredible gateway for accessing these assets, and Metals.io is a great showcase of how the future of RWA investing is taking place on Tezos,” said Dimitrios Kavvathas, Founder of Noemon Tech Ltd.

Metals.io uses the same underpinning technology as the uranium.io platform that launched on Etherlink, the EVM interface for Tezos, in December 2024. Uranium.io was purpose-built to minimise barriers to investing in uranium ore concentrate (U3O8), the asset that is used in nuclear reactors and could be key to powering the AI revolution. Since launching, uranium.io has played a pivotal role in bridging the multi-billion-dollar traditional commodity market with the speed and transparency of decentralized finance (DeFi), welcoming new investors who would not previously have had the opportunity to own and trade the commodity. The platform has received widespread industry recognition for these innovations, including winning the Best New Product award in the Innovation in Crypto & Web3 category at the latest Benzinga Global Fintech Awards. Now, metals.io is leveraging this successful model to facilitate access to other in-demand assets such as gold and other critical base metals.

“Throughout the 21st century, gold has consistently proven itself as one of the world’s premier assets, delivering stability and preserving wealth when traditional markets waver. VNX Gold (VNXAU) brings this enduring value into the modern era by offering digital tokens that represent verifiable proof of ownership of allocated gold, held in high-security vaults. By combining the strength of industry-leading custodians with the transparency and immutability of blockchain technology, we provide investors with all the security of physical gold, elevated with the efficiency, divisibility, and flexibility of a digital asset, allowing gold to become a fractional and programmable asset that can participate in modern on-chain financial services. Built on the robust and energy-efficient Tezos blockchain, VNX Gold (VNXAU) is making verifiable gold ownership accessible to a new generation of investors,” said Alexander Tkachenko, CEO and Founder, VNX.

Commenting on the launch of Metals.io, Arthur Breitman, co-founder of Tezos, said, “Commodity markets are global and indispensable, yet access to them remains fragmented and layered with intermediaries. As the AI revolution accelerates, energy and critical materials are becoming core economic constraints. Tokenization streamlines ownership and transfer of these assets at a global scale. Metals.io represents the maturation of that model, bringing essential commodities directly onto modern digital rails.”

The latest addition to CURED’s sleep and stress relief lineup arrives on the heels of a sellout launch.

BOULDER, CO (March 30, 2026) – CURED Nutrition, a health and wellness brand harnessing the power of microdosed cannabinoids and functional mushrooms, today announced the launch of a strawberry flavor of its best-selling Dream Gummies. The new flavor is available now at curednutrition.com alongside the original grape.

Dream Gummies rank among CURED’s top-selling products — and for good reason. When the line debuted in November 2025, it sold out within two weeks, signaling a growing consumer demand for credible, third-party tested sleep support. In a 1,000-person study, participants who used CURED products for seven days reported significantly reduced stress and increased feelings of calm and physical ease — making the transition to restful sleep measurably simpler.

“Sleep is the foundation of overall health, and our 235,000+ customers trust us to support their end-of-day unwind in a clean, sustainable way. Dream was built to honor that trust,” said Joseph Sheehey, CEO and Co-Founder of CURED Nutrition.

Dream Gummies combine a precision cannabinoid and botanical formula — CBD, CBN, and a microdose of THC, paired with valerian root, passionflower, and chamomile. The result is deep, restorative sleep without the intoxicating effects of high-dose THC or the next-day fog common to most sleep supplements.

“Dream gummies are the perfect combo of my go-to plants for helping me fall asleep,” said Heather K., a verified user of CURED’s Dream gummies and a CURED Nutrition influencer. “Perimenopause is no joke when it comes to a good night’s sleep, and these gummies are exactly the potency I was hoping for to help my body sleep deep!” 

You can see more of Heather’s reviews of CURED’s products on her Instagram profile, linked here: https://www.instagram.com/cleanerliving.heatherk/?hl=en

CURED’s microdose approach uses approximately one-tenth the THC found in a standard edible — enough to deliver subtle, functional benefits like reduced stress, elevated mood, and improved quality of life, without the high. Every batch is produced in the United States and third-party tested for purity and potency.

New Delhi: The upcoming India Pharma 2026 is set to spotlight India’s transition from volume-driven production to an innovation-led growth model in the pharmaceutical sector.

Industry leaders and policymakers are expected to use the platform to highlight the need for stronger research and development, advanced manufacturing, and greater global competitiveness. The focus is shifting from producing large quantities of generic medicines to developing high-value drugs, novel therapies, and cutting-edge technologies.

Experts believe this transition is crucial for India to strengthen its position in the global pharmaceutical landscape. While the country has long been known as a major supplier of affordable medicines, the next phase of growth will depend on investments in innovation, quality, and intellectual property.

The event will also provide an opportunity to discuss regulatory reforms, collaborations between industry and academia, and strategies to boost exports. Participants are likely to explore how emerging technologies and digital solutions can further enhance efficiency and innovation in the sector.

With growing global demand for advanced healthcare solutions, India Pharma 2026 is expected to serve as a key platform to shape the future direction of India’s pharmaceutical industry.

Today’s markets analysis on behalf of Joseph Dahrieh, Managing Director at Tickmill

Oil prices extended their upward trajectory on Monday, supported by escalating geopolitical tensions and mounting concerns over supply disruptions. The closure of the Strait of Hormuz continued to fuel global supply fears. At the same time, the possibility a secondary disruption in the Red Sea is adding to the concerns.

Supply-side risks are being further amplified by the potential for military escalation. Additional U.S. troop deployments and ongoing attacks on key energy infrastructure are reinforcing concerns over sustained tensions and disruptions, underpinning the current bullish momentum in crude markets.

Looking ahead, oil prices are likely to remain highly sensitive to geopolitical developments. Any escalation affecting key maritime routes could drive further upside, particularly if multiple chokepoints are simultaneously compromised. Conversely, the reopening of the Strait of Hormuz could alleviate some of the upward pressure. However, given the scale of current disruptions, normalization in supply flows in the event of a de-escalation may take time, suggesting that oil prices could still remain elevated.

New Delhi: Himachal Pradesh Governor Shiv Pratap Shukla met Prime Minister Narendra Modi in New Delhi to discuss a range of important initiatives and developments in the state.

During the meeting, the Governor apprised the Prime Minister of ongoing welfare programmes, administrative priorities, and efforts aimed at strengthening infrastructure and public services in Himachal Pradesh. He also highlighted steps being taken to promote sustainable development and improve the overall quality of life for residents.

The discussion included key sectors such as rural development, healthcare, and tourism, which continue to play a vital role in the state’s growth. The Governor shared updates on recent progress and sought continued support from the Centre for upcoming projects.

Prime Minister Modi appreciated the efforts being made in the state and reiterated the Centre’s commitment to supporting Himachal Pradesh’s development journey. The meeting reflects ongoing coordination between the state and the Centre to ensure effective implementation of policies and programmes.